Role of Cabergoline in the Management of Uterine Fibriods: An Emerging Perspective

Abstract

Background: Uterine fibroids are the most common benign tumors in women of reproductive age, often associated with symptoms such as menorrhagia, pelvic pain, and infertility. Conventional treatments have limitations, prompting the search for effective non-surgical alternatives.

Aim and Objectives: To evaluate the efficacy and safety of cabergoline in the management of uterine fibroids, with respect to reduction in fibroid size and improvement in clinical symptoms. Materials and Methods: This prospective interventional study was conducted in the Department of Obstetrics & Gynaecology at NRI Medical College & Hospital from 2024 to 2025. A total of 50 women diagnosed with uterine fibroids were included. Cabergoline was administered at a dose of 0.5 mg twice weekly for 3 months. Patients were assessed clinically and radiologically before and after treatment.

Results: The majority of patients (36%) belonged to the 41–50 years age group. Menorrhagia was the most common presenting symptom (60%). Significant reduction in fibroid size was observed in 56% of patients, while 28% showed mild reduction. Symptomatic improvement was noted in 70% of patients. Adverse effects were minimal, occurring in only 16% of cases.

Conclusion: Cabergoline is an effective, safe, and well-tolerated medical therapy for uterine fibroids, offering a cost-effective and fertility-preserving alternative to conventional treatments.